Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Company Description
Electro supplies laser-based manufacturing solutions for the microtechnology market for precise structuring and testing in semiconductors and other components.
Top Line Jumps 72%
Electro reported fourth-quarter and full-year results on May 10 and they included and impressive 72% increase in annual revenue, to $257 million.
Net income for the quarter came in at $6.0 million, up from $2.4 million a year ago. That breaks down to $0.21 per share, up from $0.08 and beat the Zacks Consensus Estimate by a nickel. This was the fourth earnings surprise in the past 5 quarters.
Bullish Outlook
Electro sees a healthy market heading into fiscal 2012, with strong demand and good positioning. Analysts seemed to agree, raising their estimates for the upcoming quarter and year.
The Zacks Consensus Estimate for this year is up 9 cents, to $0.81. Next year's average estimate rose 7 cents, to $0.97. Given the $0.34 per share earned in 2011, expected growth rates are now 138% and 20%, respectively.
Buy on the Dip?
Shares of ESIO have taken a hit the past few weeks, but given the rising estimates this could be a good "buy on the dip" opportunity. Shares are trading at roughly 19 times this year's estimates, with a PEG of 1.4 and a price-to-book of 1.3.
Bill Wilton is the Aggressive Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Small Cap Trader service
Read the full reports :
Snapshot Report on ESIO